Cargando…
Remission of CVB3-induced myocarditis with Astragaloside IV treatment requires A20 (TNFAIP3) up-regulation
Viral myocarditis (VMC) most prevalently caused by coxsackievirus B3 (CVB3) infection is characterized by severe cardiac inflammation. Therapeutic options for the disease are still limited. Astragaloside IV (AST-IV), a purified small molecular saponin (C(41)H(68)O(14), MW 784), is the main active co...
Autores principales: | Gui, Jun, Chen, Ruizhen, Xu, Wei, Xiong, Sidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395199/ https://www.ncbi.nlm.nih.gov/pubmed/25728713 http://dx.doi.org/10.1111/jcmm.12459 |
Ejemplares similares
-
A20 (TNFAIP3) Alleviates CVB3-Induced Myocarditis via Inhibiting NF-κB Signaling
por: Gui, Jun, et al.
Publicado: (2012) -
Intein-mediated backbone cyclization of VP1 protein enhanced protection of CVB3-induced viral myocarditis
por: Qi, Xingmei, et al.
Publicado: (2017) -
Direct Gene Transfer with IP-10 Mutant Ameliorates Mouse CVB3-Induced Myocarditis by Blunting Th1 Immune Responses
por: Yue, Yan, et al.
Publicado: (2011) -
Dpep2 Emerging as a Modulator of Macrophage Inflammation Confers Protection Against CVB3-Induced Viral Myocarditis
por: Yang, Xiaoli, et al.
Publicado: (2019) -
An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine
por: Gao, Yue, et al.
Publicado: (2021)